- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Locally advanced (stage IIIB) or metastatic (stage IV) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
- Meeting Date: December 2021
- Public Summary Document (PSD) December 2021 PBAC Meeting - (PDF 609KB)
- Public Summary Document (PSD) December 2021 PBAC Meeting - (Word 88KB)
Lorlatinib – December 2021
Lorlatinib: Tablet 25 mg, Tablet 100 mg; Lorviqua®
Last updated
1 April 2022